Inhibiting soluble epoxide hydrolase as a treatment for chemotherapy inducedperipheral neuropathic pain
Award amount
$268,196Program and phase
SBIR · Phase IAward year
2019Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- EICOSIS LLC
- Proposal award date
- 2019-09-25
- Contract end date
- 2021-02-28
- UEI
- EM8CCFVCTV69
- Solicitation number
- PA18-574
- Topic code
- 102
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Identification of mechanism-based therapies to treat arrhythmogenic cardiomyopathy by resolving perturbations in regulatory lipid signaling
- sEH Inhibitors to Treat Neuropathic Pain
- sEH Inhibitors to Treat Neuropathic Pain
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- MiREA, a mHealth intervention to Reduce Health Disparities by Improving Equitable Access to Mandated College Students with Problematic Alcohol and Marijuana Use
- Modex, a cloud-based, centralized health economic model marketplace to reduce costs and enhance equity in cancer
- Precision screening in self-collected samples to reduce cervical cancer disparities among Latinas
- Allogeneic cell and gene therapy for neuroendocrine tumors
- Nanoparticle formulation of Mediator kinase inhibitor for the treatment of peritoneal ovarian cancer
Research funding history
4 SBIR/STTR records share this UEI (2014–2022). Reported award amounts total $2,286,255. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services